# GHK-Cu Dosage in Research: Concentrations, Routes, and Stability | GHK-Cu Order > GHK-Cu dosage as studied: fibroblast concentrations of 10^-12 to 10^-9 M, topical 0.05-2% formulations, rodent IP/intranasal protocols, the half-life question, and formulation stability. The concentrations, routes, and stability conditions documented in the literature — research context only, never a human dosing instruction. ## Concentrations and routes in the studied record GHK-Cu dosage in the research literature spans cell culture to rodent systemic work, and none of it constitutes a human dosing recommendation. In vitro, fibroblast collagen synthesis was driven at 10^-12 to 10^-9 M, with onset at 10^-12 to 10^-11 M and a peak near 10^-9 M [1]. Topical cosmetic and clinical formulations have used roughly 0.05% to 2% (w/w) in creams, serums, and gels [4]. Rodent systemic studies used defined protocols: intraperitoneal dosing in mouse pulmonary models and milligram-per-kilogram ranges in silicosis and colitis models, plus intranasal dosing in aging and cognition studies [5]. The human exception is topical: the ALAVAX 5-ALA + GHK hair-loss trial applied 50 to 100 mg/mL to the scalp over six months [7]. Routes documented across the record include topical (cream, serum, liposome, microemulsion, hydrogel, nanofiber), intraperitoneal, intranasal, oral gavage, and intravenous/subcutaneous in rodents [5]. ## What the in-vitro dose-response actually fixes The cell-culture numbers are the most precise figures in the GHK-Cu record, and they anchor everything else. Collagen synthesis in human fibroblasts began at 10^-12 to 10^-11 M and maximized near 10^-9 M, with no change in cell number — so the active concentration window is picomolar to nanomolar, and the effect is metabolic rather than proliferative [1]. The AHK-Cu analog showed follicle and dermal-papilla effects across the same 10^-12 to 10^-9 M range, with apoptosis reduction at 10^-9 M, which is consistent with a shared copper-tripeptide concentration window [9]. Biomaterial studies use higher working concentrations because the peptide is bound or released from a matrix rather than freely dosed: GHK-modified alginate showed no cytotoxicity from 1 to 500 ng/mL while driving VEGF secretion [13], and GHK-Cu scaffold coatings used a 1 mM coating solution to improve fibroblast viability [14]. These are formulation concentrations, not systemic doses, and they describe what the material delivers locally rather than what reaches circulation. ## The human record, and what it does not cover The human dosing record is narrow and almost entirely topical. Small placebo-controlled facial cream and serum trials (roughly n=13 to 71) reported improved skin density, firmness, fine lines, and wrinkle depth, and the 45-patient ALAVAX hair-loss trial applied a 50 to 100 mg/mL 5-ALA + GHK combination to the scalp over six months [4][7]. A topical wound-healing trial has been registered, but there are no completed Phase 2 or Phase 3 trials for systemic or injectable GHK-Cu [4]. That gap is the central caution for the dosing question. No FDA- or EMA-approved therapeutic GHK-Cu product exists by any route; topical Copper Tripeptide-1 is a legal cosmetic ingredient, while injectable and oral systemic formulations are unapproved research chemicals [4]. Injectable dosing protocols that circulate in community contexts have no peer-reviewed human pharmacokinetic basis, which is why this page describes only what was administered in specific species and models — never a human dose to take [4]. ## The half-life question No rigorous human pharmacokinetic half-life for GHK-Cu has been published [4]. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases, and the copper-chelated complex is more stable than free GHK [5]. Secondary literature cites a short systemic elimination half-life on the order of one to two hours, but that figure is not a validated human parameter [4]. The stability difference between the two forms is the part with a clear mechanistic basis. The copper complex's very high stability constant (log K ~16.4) holds the metal tightly, which both limits pro-oxidant free-copper release and makes the chelate more robust than the bare peptide [5]. That is a statement about chemical stability, not a measured circulating half-life — the distinction matters because the absence of validated human Cmax, bioavailability, and tissue-distribution data is exactly the gap this digest marks as the drop-off step [4]. Topical application changes the time course locally. The human skin penetration study measured 97 +/- 6.6 ug/cm^2 of copper retained as a dermal depot over 48 hours, which is the mechanistic basis for prolonged local availability after a topical dose [10]. So the pharmacokinetic picture is split: poorly characterized systemically, depot-forming topically. ## Formulation stability and incompatibilities The GHK-Cu complex is stable because its copper stability constant is high (log K ~16.4), which limits pro-oxidant free-copper release; it is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio [5]. The blue-violet color of a reconstituted solution indicates an intact Cu(II) complex; a brown or green shift indicates oxidation or precipitation [5]. The practical incompatibility is reducing agents and low-pH actives. Ascorbic acid (vitamin C) below about pH 3.5 reduces Cu(II) and breaks the complex, and AHAs, BHAs, and salicylic acid can destabilize it or compete for copper [5]. Free GHK's high hydrophilicity (clogP -2.24) limits passive skin penetration, which is why palmitoylation, liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment are studied as delivery enhancements [15]. ## Why delivery, not dose, dominates the topical story For a topical compound this hydrophilic, the route and vehicle matter more than the nominal concentration. The human penetration study quantified the problem and the opportunity at once: copper crossed dermatomed skin at a permeability coefficient of 2.43 +/- 0.51 x 10^-4 cm/h and left a 97 +/- 6.6 ug/cm^2 dermal depot over 48 hours [10]. The 2025 review frames poor stratum-corneum permeability (free GHK clogP -2.24) as the central delivery challenge and reports microneedle pretreatment moved about 134 nmol of GHK through skin versus essentially none through intact skin [15]. The research vehicles follow from that constraint. Liposomal encapsulation, ionic-liquid microemulsions, and palmitoylation (Pal-GHK, clogP 1.14) raise lipophilicity for passive uptake [15], while biomaterials deliver the peptide from a matrix: a photo-crosslinkable hyaluronic-acid hydrogel with GHK nanofibers and a GHK-Cu-coated scaffold both improved fibroblast outcomes over free peptide or uncoated controls [12][14]. None of these is a dose in the pharmaceutical sense — they are delivery formats, and the field's open question is translation to validated human outcomes, not a milligram figure to recommend [4]. --- The GHK-Cu copper-tripeptide literature charted as one pipeline — the strong steps logged green, the missing human pharmacokinetics marked as the amber drop-off, and no clinic or vendor on either side of the funnel.